13 security-"https:"-"https:"-"https:"-"https:"-"IFM" research jobs at Center for Biologics Evaluation and Research (CBER)

FDA Fellowship - Immune Globulin Safety and Efficacy in Pregnant and Neonatal Populations

Center for Biologics Evaluation and Research (CBER) | Southern Md Facility, Maryland | United States | about 9 hours ago

safely, adhering to all the laboratory and personnel safety rules and regulations during appointment activities; Effectively communicate research findings using poster/oral presentations, and written

FDA Fellowship - Understanding the Role of the Manufacturing Microenvironment on the Safety and Efficacy of Cellular Therapies

Center for Biologics Evaluation and Research (CBER) | Silver Spring, Maryland | United States | 13 days ago

the safety, purity, potency, and effectiveness of biological products including vaccines, blood and blood products, and cells, tissues, and gene therapies for the prevention, diagnosis, and treatment of human

FDA Fellowship - Developing Novel Strategies to Improve Safety, Efficacy and Quality of Gene Therapy Products

Center for Biologics Evaluation and Research (CBER) | Southern Md Facility, Maryland | United States | 13 days ago

applications (BLA) being submitted to the FDA, there is a need to develop innovative analytical methods and regulatory science approaches to comprehensively evaluate the safety, efficacy, and quality

FDA Fellowship - Immune Globulin Safety and Efficacy in Pregnant and Neonatal Populations

Center for Biologics Evaluation and Research (CBER) | Southern Md Facility, Maryland | United States | 13 days ago

safely, adhering to all the laboratory and personnel safety rules and regulations during appointment activities; Effectively communicate research findings using poster/oral presentations, and written

FDA Postdoctoral Fellowship - Enhancing the Safety and Efficacy of Immune Cell and Gene Therapies

Center for Biologics Evaluation and Research (CBER) | Silver Spring, Maryland | United States | about 9 hours ago

including blood, vaccines, allergenics, tissues, and cellular and gene therapies. Research Project: CBER’s mission is to ensure the safety, purity, potency, and effectiveness of biological products including

FDA Postdoctoral Fellowships in Cell and Gene Therapy

Center for Biologics Evaluation and Research (CBER) | Silver Spring, Maryland | United States | 12 days ago

the regulation of biological and related products including blood, vaccines, allergenics, tissues, and cellular and gene therapies. Research Projects: Project Area 1: Cell and Gene Therapy Safety This project

FDA Postdoc - Investigating Host–Pathogen Interactions to Develop Next-Generation Sequencing-Based Assays for Comprehensive Microbial Surveillance in Biologics

Center for Biologics Evaluation and Research (CBER) | Southern Md Facility, Maryland | United States | about 9 hours ago

pathogens and adventitious agents, thereby improving product safety. This project aims to establish a comprehensive surveillance platform that combines Illumina short-read and PacBio HiFi long-read sequencing

FDA Prophylactic Vaccine Against Visceral Leishmaniasis Post-doctoral Fellowship

Center for Biologics Evaluation and Research (CBER) | Silver Spring, Maryland | United States | 13 days ago

, and cellular and gene therapies. Research Project: The FDA laboratory has been conducting collaborative research on the evaluation of safety and efficacy characteristics of live attenuated Leishmania

FDA Fellowship - Cell Membrane Microparticles and Nanoparticles

Center for Biologics Evaluation and Research (CBER) | Silver Spring, Maryland | United States | 12 days ago

activities of platelet EVs in DMSO cryopreserved platelets (CPP) and other platelet products may significantly impact their safety and efficacy. This project establishes characterization criteria for EVs, as

FDA Fellowship - Immunogenicity of Gene Editors

Center for Biologics Evaluation and Research (CBER) | Silver Spring, Maryland | United States | about 9 hours ago

Cas proteins. You will help identify promiscuous immunogenic epitopes in emerging Cas proteins and develop new tools to understand the safety consequences of immune responses to neo-epitopes generated